HLB BioStep Co

HLB BioStep Co Assets per Share

The Total Assets per Share of HLB BioStep Co (278650.KQ) as of Oct 28, 2026 is 1,813.94 KRW. In the previous year, Total Assets per Share was 1,962.64 KRW — a change of -7.58% (lower).

Assets per Share

1,813.94KRW

YoY

-7.58%

Last updated:

Total Assets per Share of HLB BioStep Co is 2025 1,813.94 KRW. Total Assets per Share of HLB BioStep Co was 2024 1,962.64 KRW. It decreases by -7.58% lower compared to the previous year.

The HLB BioStep Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
510.00 KRW
Jan 1, 2019
717.42 KRW
Jan 1, 2020
865.32 KRW
Jan 1, 2021
1,103.29 KRW
Jan 1, 2022
2,007.62 KRW
Jan 1, 2023
2,002.11 KRW
Jan 1, 2024
1,962.64 KRW
Jan 1, 2025
1,813.94 KRW
The HLB BioStep Co Assets per Share history
YEARAssets per ShareYoY
1,813.94KRW-7.58%
1,962.64KRW-1.97%
2,002.11KRW-0.27%
2,007.62KRW+81.97%
1,103.29KRW+27.50%
865.32KRW+20.62%
717.42KRW+40.67%
510.00KRW+33.68%
381.51KRW+67.56%
227.69KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

Total Assets per Share of HLB BioStep Co is 1,813.94 KRW in 2025.

Total Assets per Share of HLB BioStep Co changed from 1,962.64 KRW to 1,813.94 KRW, representing a -7.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — HLB BioStep Co

All Key Metrics — HLB BioStep Co